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A growing body of evidence supports a role for catecholaminergic dysfunction 
in the core symptoms of autism spectrum disorder (ASD). This paper reviews the 
direct and indirect role of catecholamines on the central and peripheral nervous 
systems in ASD. Catecholamines innervate every tissue in the body and almost 
all tracts of the brain, providing a common neurologic regulatory mechanism for 
all ASD symptoms. Because the morphology of the catecholaminergic synapse 
is regulated by growth factors that are released contemporaneously with neu-
rotransmitters, an event that results in abnormally large catecholamine release, 
will also release high levels of growth factors, which can result in the budding and 
arborization of nerve terminals. Here, we hypothesize that a hypertrophic synaptic 
morphology can occur in catecholaminergic systems and increase catecholaminer-
gic tone throughout the body, resulting in an imbalance between catecholaminergic 
neurologic mechanisms and those that oppose them, and consequently pathol-
ogy. By exerting a presynaptic effect to inhibit tyrosine hydroxylase and thus the 
synthesis, storage and release of all catecholamines, L1–79 (a tyrosine hydroxylase 
inhibitor) may diminish neurotransmitter release and its associated growth factors 
exerting a therapeutic effect on ASD by reducing the hypertrophic morphology 
of the synapse and bringing catecholamines back into a homeostatic balance with 
oppositional neurologic and metabolic influences.
Keywords: autism, autism spectrum disorder, catecholamines,  
D, L-α-methyl-para-tyrosine, L1–79
1. Introduction
Childhood autism is more prevalent than childhood cancer, juvenile diabetes 
and pediatric AIDS combined, with an estimated prevalence of 3 M children in 
Europe, 1.5 M in the US, and tens of millions throughout the rest of the world. More 
disturbing is that for no explicable reason childhood autism appears to be increas-
ing at a rate of 10–17% per year [1]. Typically displayed in early childhood, autism 
may be associated with many co-morbidities that include epilepsy, attention deficit/
hyperactivity disorder (ADHD), abnormal sensory or motor responses, disturbed 
sleep, reduced cognitive functionality, anxiety and aggression [2–4], or none at all.
In 2019 the CDC reported the rate of autism in the US to be 1 in 59 children, with 
boys being 4 times more susceptible than girls [5]. This means that 1 in 42 boys are 
diagnosed with autism. There was an increase of about 30% since the assessment 
of autism prevalence conducted previously (Table 1), and more almost 3x the rate 
that was reported only 20 years ago. In New Jersey the observed rate of autism was 
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1 in 46 children, which means that 1 in 29 boys born in New Jersey are likely to be 
autistic [6, 7].
The lifetime cost of raising an autistic child was estimated in 2014 to be $3.2 M 
more than the cost of raising a non-autistic child [8], and this does not take into 
account the societal costs of maintaining these this population as adults once their 
families are no longer able to do so. The societal costs of autism are broad and deep, 
and many have never been explored. For example, it was only in mid-2017 that 
information was developed on the rate of healthcare utilization by autistics and it 
was found that their need for psychiatric care as well as care for the high incidence 
of autism associated comorbidities was far beyond that of the general population or 
other elements of the psychiatric patient population [9]. Similarly, it was not until 
September of 2017 that the rate of school suspension and expulsion was dramati-
cally higher in the autistic population, and growing as the autistic population grew 
in numbers [10].
Recently, attention has been brought to bear on autism associated mortality rates. 
Although autism is not typically considered to be a fatal disease, several investiga-
tors have reported a significantly increased mortality in the autistic population 
with the major cause of death being suicide. A matched case cohort study based 
upon the Swedish National Patient Registry and the Cause of Death Registry looked 
at deaths between 1987 and 2009 and found a 256% greater death rate in autistic 
patients compared to the general population. The mean age at the time of death was 
70.2 years for the general population and 58.39 for patients with autism, with suicide 
associated with better performing patients [11]. A review of 1706 children and 
adolescents reported an 18% increased risk of suicidal ideation or attempts in autism 
[12]. 35% of patients with Asperger’s syndrome were reported in a Canadian study 
t have attempted suicide [13]. Similarly, in Japan [14], Australia [15], England [16], 
and Belgium [17]. In a French review of the PubMed literature it was found that 
overall 21.3% of autism patients reported suicidal ideation or had attempted suicide, 
with the noteworthy observation that “… the methods used are often violent” [18].
Autism is quite heterogenous and has a broad pallet of potential symptoms. 
These symptoms transcend established investigative disciplines including behav-
ioral studies, developmental studies, neurology, pharmacology and so forth. No 
truly workable definition of autism has yet emerged to define this heterogenous 
constellation of symptoms. Theories regarding the causes of autism include impair-
ments within the autonomic nervous system [19], cerebellar dysfunction [20], 
mitochondrial impairment [21], exposure to toxins [22], and many others.
Identified Prevalence of Autism Spectrum Disorder
ADDM Network 2000-2010





Number of ADDM 
Sites Reporting
Prevalence per 1,000 
Children (Range)
This is about 1 in X 
children…
2000 1992 6 6.7 (4.5–9.9) 1 in 150
2002 1994 14 6.6 (3.3–10.6) 1 in 150
2004 1996 8 8.0 (4.6–9.8) 1 in 125
2006 1998 11 9.0 (4.2–12.1) 1 in 110
2008 2000 14 11.3 (4.8–21.2) 1 in 88
2010 2002 11 14.7 (5.7–21.9) 1 in 68
Table 1. 
CDC: Prevalence of autism in the US [5].
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2. Autonomic function and autism
The autonomic nervous system has been implicated in symptoms that resemble 
those seen in autism. ASD has been associated with abnormal findings in auto-
nomic related structures including the insula [23, 24] and the amygdala [25–27]. 
Autonomic related changes such as increases in basal heart rate [28–31] and dimin-
ished heart rate variability due to psychosocial challenges [32, 33] are seen in autism. 
The autism-autonomic linkage is exemplified by the consequences of respiratory 
sinus arrhythmia (RSA) that includes difficulties with socialization [30, 34], 
language difficulties [34, 35], and delays in cognitive development [35].
Kushki [19] hypothesized a chronically over activated autonomic system is a 
correlate of autism based upon the exaggerated levels of anxiety that attend autism 
[33], physiologic hyperarousal [36–38], and other correlates. Anxiety is perhaps the 
greatest co-morbidity associated with autism which may drive other features of the 
disease [39, 40], and has been associated with central nervous system structures 
that are linked to autonomic function [41, 42]. Phenotypically autism and anxiety 
both present with stereotyped repetitive and limited interests, avoidance behaviors 
and speech problems [43–45]. The relationship between anxiety and reported 
autonomic symptoms of elevated heart rate, perspiration, and other sequelae of the 
“fight or flight” reaction reveal a role for the peripheral nervous system function in 
autism [36–38]. However, this may be secondary to central autonomic activation. 
Central functions may manifest as elevated emotional responsiveness and exagger-
ated threat perception or diminished inhibition of fear responses [36], which are 
associated with the central structures mentioned above in which autonomic respon-
siveness and emotional responsiveness overlap.
There is a considerable body of evidence, which will not be reviewed here, 
that associates autism with cholinergic function in the central nervous system, 
specifically with various α-subtype nicotinic receptors, notably in the cerebellum. 
However, as autonomic function is classically considered to be a balance of cholin-
ergic and catecholaminergic systems, perceived increases or decreases in cholinergic 
function may be manifestations of change in the dynamic balance of these systems 
with catecholaminergic tone. It may be possible to effect therapeutic change 
through manipulation of either acetylcholine-based manipulations or the counter-
balancing of dopamine, norepinephrine, or epinephrine mediated mechanisms.
3. Adrenergic CNS changes in autism
Recent work by Hamilton, et al. [46] who sequenced exomes of families with 
a history of autism found deficiencies in the human dopamine transporter gene 
(hDAT), a protein responsible for the presynaptic reuptake of dopamine. CNS 
dopamine is a crucial element in systems that mediate motor function, motiva-
tion, attention and reward [47–50]. As this system is known to be associated with 
ADHD, and approximately 45% of autistic patients manifest symptoms of ADHD 
[3, 51–53], there is reasons to suspect a common pathway underlying these two 
diseases. Moreover, dopamine related genes DRD1, DRD3 and DRD4 are associ-
ated with an increased risk for ASD [54] as well as repetitive stereotyped behavior 
[55–57], and defiant and anxiety disorders [56]. Males with multiple tandem repeats 
in the monoamine oxidase-A (MAOA) promotor gene responsible for degrading 
dopamine show in increased proclivity for autism [58]. Aside from changes in 
synaptic dopamine uptake and degradation, changes dopamine receptor function 
and avidity have been reported [59–61], as have changes in dopamine synthesis 
and DOPA decarboxylase. Additionally, it has been observed that pharmacologic 
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manipulation of dopamine has clinical efficacy in ASD [62, 63], for example with 
risperidone, a drug approved to treat ASD.
Other lines of support come from observations of lower levels of dopamine 
β-hydroxylase in the plasma of autistic patients [64, 65] and reductions in platelet 
[66] and urine dopamine [67]. Similarly, inferences have been published that the 
mesolimbic cortex and striatum may provide a neurologic substrate linked with 
the motor and behavioral symptoms seen in autism as a result of a dopaminergic 
imbalance in these structures [68, 69].
Nguyen et al. [70] used in silico methods to clarify the genetics underlying the 
contribution of dopamine the etiology and pathogenesis of autism and found genes 
implicated that regulate both Ca++ metabolism and dopaminergic neurotransmis-
sion. They found proteins implicated in ASD regulate dopamine signaling in mul-
tiple places including reuptake and catabolism, and they defined discrete molecular 
clusters that act on systems implicit in dopaminergic systems such as androgen 
receptors that stimulate DOPA decarboxylase. Another finding was the potential 
role of dopamine mediating the modulation of dendritic spines which determine 
synaptic strength and may be important in the developmental delays associated 
with ASD [71].
In an interesting cybernetic model, Kriete and Noelle [72] developed a sophisti-
cated methodology to investigate the role of dopamine and the changes in executive 
function associated with autism. They showed that the intensely focused cognition 
associated with autism, as well as the pathognomonic lack of cognitive plasticity 
and inability to react with appropriate conscious focus to changes in the stimulus 
milieu could be modeled as changes in dopaminergic systems in the prefrontal 
cortex. By differentiating cognitive control from plasticity, and further by showing 
how developmental changes in younger brains can account for the timing of the 
manifestation of autistic symptoms, these authors findings support a causal adren-
ergic mechanism underling at least some of the symptoms associated with autism.
Taken together, a good case can be made for dopamine as a key mediator of 
the motor, speech, social behavior, behavioral perseveration, and reward aberra-
tions that are typical symptoms of autism. The precise regulation of dopaminergic 
function of autonomic function appears to involve the projection of Purkinje cells to 
the medial prefrontal cortex (mPFC) and the ventral tegmental area (VTA) of the 
striatum. Atrophied Purkinje cells is one of the most consistent neuropathologies 
associated with autism [73–76], and MRI data indicates persons with autisticism 
have smaller than normal cerebellar vermal volume [77]. Mice with diminished 
Purkinje cell mass evidence numerous autistic symptoms such as repetitive behav-
iors and impaired executive function [78]. Cerebellar Purkinje cells project to the 
mPFC where it appears they modulate dopaminergic transmission in this region 
directly, and via a remodeling of the VMA and thalamic interactions with the 
mPFC, and it has been suggested that cerebellar deficits observed in autism result in 
cortical, thalamic, and striatal integration via dopamine mediated pathways [79].
An immunologic linkage of dopaminergic function in autism was reported by 
Kirsten et al. [80] when they prenatally exposed rat pups to lipopolysaccharide, a 
stimulator of innate and adaptive immunity. Autistic symptoms of impaired com-
munication, deficits in learning and memory, and repetitive/restricted behavior 
were observed in the presence of impaired tyrosine hydroxylase (TH) function 
which was taken as a marker of reduced striatal dopaminergic function. Support 
for this concept was also found when rat pups were given poly I:C, an immunogenic 
stimulator, and upregulation of various genes associated with dopamine neural 
development were observed [81].
The phosphatase and tensin homolog on chromosome ten (PTEN) is tumor 
inhibitory gene that inhibits PI3K and MAPK pathways, and a germline mutation of 
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this gene has been associated with autism [82]. Mouse mutations of this gene have 
resulted in symptoms similar to autism [83], and PTEN deletions have been found 
to enhance the survival and the function of dopaminergic neurons [84]. Work in 
this area has shown that mice with PTEN mutations have elevated TH and DA2 
receptors in the striatum and prefrontal cortex, that PTEN reduces TH phosphory-
lation via MAPK suppression, downregulates dopamine synthesis in PC12 (pheo-
chromocytoma) cell cultures, and that a PTEN-TH pathway may function as a “core 
regulator of dopamine signaling”. Moreover, this mechanism appears to be operative 
in autistic patients, as 3 PTEN mutants identified in autistic patients cannot sup-
press TH, which supports the concept of TH suppression as a potential mechanism 
for therapeutic intervention in autism [85].
Consistent with the finding that TH over activity might underlie the symptoms 
of autism is the finding by D’Souza et al. [86] that the commonly used model for 
autism in which symptoms in animals are induced by administering valproic acid 
is related to the ability of this agent to induce TH transcription at every concentra-
tion tested.
4. GI abnormalities in ASD
Autism is associated with gastrointestinal pathology from the esophagus to the 
colon [87–91]. The literature suggests that GI pathophysiology is an intrinsic com-
ponent of autism in many patients and may be a central component to the etiology 
of the disease. GI problems have been reported in 42% of children with ASD and 
12% of controls, with chronic diarrhea and constipation being the most prevalent 
problems. The severity of these problems correlates with the severity of ASD [92]. 
It is noteworthy that in both GI dysfunction and ASD imaging reveals abnormalities 
in brain regions associated with emotional and sensory functions [93, 94], and GI 
problems contribute to behavioral problems, attentional deficits, and self injury 
[95]. Gut bacteria influence intestinal permeability, mucosal immunity, the enteric 
nervous system, pituitary functions, and the modulation of pain (cited [96]).
There is increasing reason to believe that the interaction between gastric 
microbiota and the brain are contributory to the symptoms seen in ASD. This is 
mediated via the autonomic innervation of the intestine and the hypothalamic–
pituitary axis which is innervated by catecholamines and which generates GI 
signaling molecules affecting enteroendocrine and mucosal immune cells. The 
“Gut Brain Axis” is comprised of central and peripheral nervous systems as well 
as the neuroendocrine and immune systems, and communication is bidirectional, 
with vagal inputs to the brain as well as endocrine and neuroendocrine signaling 
[97]. Catecholamines are associated with stress reactions and, interestingly, GI 
microbiota respond to stress with changes in their efferent and afferent catechol-
amine responses (reviewed in [98]).
A trial of 36 autistic children found pain, chronic diarrhea, bloating, GI irrita-
bility, chronic gastritis, esophagitis, chronic duodenitis, diminished carbohydrate 
digestive enzymes and reduced pancreatic exocrine secretion in response to secretin 
challenge [88]. Secretin has not been found to be an effective treatment for autism. 
In a survey of parents of 500 autistic children, half responded that their children 
had loose stools or chronic diarrhea, and intolerance for wheat and cow’s milk [99]. 
A number of reports mention improvements in autistic symptoms when reduced 
gluten and casein diets are implemented and the return of symptoms when these 
diets are terminated (cited in [100]).
Lucarelli et al. [101] observed an improvement in social skills and the ability 
to communicate in a trial of 36 autistics who were given diets with diminished 
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gluten and/or cow’s milk, with improvements observed in 5 of 7 objective behav-
ioral scales. Similar findings have been reported by others [102–105]. Following 
one year on this diet symptoms returned upon termination of the dietary restric-
tions [104]. Intestinal permeability was found increased to lactose in a number 
of high functioning autistic children compared to age matched controls, with no 
increased permeability to mannitol, which was interpreted to mean a diminu-
tion in the tight junctions of gut epithelium [106] and the subsequent release 
of incomplete gluten and casein digestive products. Autistic patents reportedly 
manifest significantly higher levels of IgA for casein, gluten, lactalbumin and 
β-lactoglobulin [101, 107].
These observations give rise to the Leaky Gut Hypothesis of Autism, which 
states that various digestion products can enter the blood through leaky tight 
junctions in the gut and interact with the immune and central nervous systems in 
ways that facilitate the onset of autism. Gut peptidases release short chain peptides 
called exorphins that have structural similarity to endorphins. Gliadomorphins 
and casomorphins are stable examples of these peptides that are known to induce 
psychosis [108]. β-Casomorphin-7 is elevated in the urine of autistic patients [104], 
and when in infused into the blood stream of rats has been shown to activate the 
transcription of the gene c-Fos in the brain [109]. However, dietary restrictions do 
not cure autism.
While controversial, elevated short chain fatty acids (SCFA) have been associ-
ated with autism [110], and both central and peripheral administration of propionic 
acid (PPA) to rats induces ASD-like impairments that include aberrant motor 
movements, stereotyped repetition, EEG changes, cognitive deficits, perseveration 
and social impairment, as well as increased oxidative stress, glutathione depletion, 
neuro-inflammation, altered lipid profiles and more [111]. SCFA are digestive prod-
ucts derived from fiber and protein. The most common SCFA include propionic 
PPA and butyric acid (BA) [112]. BA and PPA are metabolized in the liver via the 
portal circulation, however areas of the distal colon are outside of the portal circu-
latory bed, and the systemic effects of BA and PPA are believed to be significantly 
underestimated [110, 112]. SCFA, including PPA, activate G protein coupled neural, 
effect neurotransmitter synthesis and release, and mediate such diverse events 
in the nervous system as Ca++ gating, mitochondrial function, lipid metabolism, 
immune function, gene expression and the role of tight junctions [110]. SCFA are 
believed to modify the activity of TH, and there are 3 ways in which the SCFA BA 
modifies TH activity: (1) modulation of transcription via chromaffin remodeling, 
(2) activation of various transcription mediators, and (3) by interfering with TH 
mRNA [113–116]. Subsequent work by Nankova, et al. [117] have shown that PPA 
elevates TH mRNA levels and that SCFA increase TH and subsequent catecholamine 
synthesis.
This dietary model allows for the elevation of cortical and striatal dopamine 
activity via elevated TH synthesis and activation, and which has been invoked as a 
potential mechanism for the actions of risperidone [118, 119], one of the two drugs 
approved for the treatment of the irritability associated with autism. It is worth 
noting in this context that PPA is structurally similar to valproic acid (VA), and 
has similar effects to VA, which is a treatment known to induce autistic symptoms, 
and used as a model for this purpose [120–122]. As cited above, VA appears to 
induce ASD- like symptoms by stimulating TH transcription in a manner similar to 
butyrate [86].
It is worth noting that relative to the participation of gastrointestinal events 
which may underlie autism, recent developments in the study of the human biome 
and investigations into GI function have revealed that the gut is the source of a 
number of neurotransmitters and neurotrophic factors, thus opening a previously 
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understudied source of pharmacologic agents which may regulate CNS function. 
E. coli and Clostridium sp. have been shown to elevate free GI catecholamines and 
dopamine increases colonic water absorption [123]. GI microbiota produce cat-
echolamines and recognize them in the environment [124–126]. Epinephrine and 
norepinephrine are implicated in the virulence, ability to adhere, and chemotaxic 
properties of luminal bacteria [127].
In the work discussed above, it is important to note that PPA activates peroxisome 
proliferator-activated receptor gamma (PPAR-γ), and that this orphan receptor has 
been shown to have independent effects on the mediation of catecholamine and 
opioid pathways by SCFA [128], and that, as discussed below, PPAR is considered 
to be a “master regulator” of lipid homeostasis both centrally and peripherally. This 
later finding plays into the growing literature of lipid metabolism dysregulation in 
autism. PPAR also has immunologic functions that have been found to be related to 
metabolic and neurologic pathologies [129].
5. Dopamine underlies autistic symptoms in the gut and the CNS
Any comprehensive approach to the treatment of autism must accommodate 
many different organ systems, certainly the gut and the CNS. As discussed above, 
the neurotransmitter function of dopamine is well known, including its modulatory 
effects on motor function, mood, emotion, irritability, reward, and other systems 
which are affected by autism. However, there also exists in the mesentery a para-
crine dopaminergic system that regulates the secretion of bicarbonate [130], the 
secretion of digestive enzymes by the exocrine pancreas [131], and which controls 
sodium transport in the lower intestine [132]. Dopamine also has documented 
effects on gut motility and mucosal blood flow [133–135]. As early as 1994 elevated 
blood levels of levels of dopamine have been associated with autism [136]. It is 
known that ASD is associated with elevated levels of dopamine in the tracts linking 
the amygdala and prefrontal cortex in children with ASD [137, 138].
What is less known is that approximately 42–46% of the dopamine in the body 
is produced in the gut. Eisenhower and colleagues at NIH [139] studied 8 patients 
undergoing elective abdominal surgery and 47 patients who underwent cardiac 
catheterization. Tissue samples from the stomach and duodenum were obtained 
and compared, as were arteriovenous concentration differences and rates of renal 
clearance of dopamine and its metabolites in conditions of different sympathetic 
nervous backgrounds for dopamine not converted to norepinephrine. They found 
considerable dopamine synthesis in the stomach, pancreas, and duodenum, with 
renal elimination of dopamine and its metabolites. Dopamine has a naturetic func-
tion in the kidney; however, there was significant overflow of dopamine into the 
renal venous circulation that allows for systemic effects. As expected, cells in the 
stomach, pancreas, and duodenum stained positive for TH. The authors could not 
account for the amount of dopamine added to the mesenteric venous circulation, 
as it cannot be explained by sympathetic activity or diet, and their results were 
consistent with findings in swine [140].
In keeping with the concepts presented herein, it is relevant that in the liver, 
bile salt production and release are also under the control of dopamine [141, 142]. 
Bile salts are known to occur not only in the periphery, but in the CNS as well, 
where they appear to contribute to neurologic decline and blood brain barrier 
permeability [143, 144]. Bile acids are the predominant steroid in the brain, with 
levels that are 10x greater than those found in the blood indicating local synthesis, 
and with higher titers than that of pregnanolone, which was once considered the 
predominant neurosteroid [145].
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In the brain, it has been observed that chenoxydecholic acid or deoxycholic acid 
induce the phosphorylation of occludin and increase the permeability of tight junc-
tions via an Rac-1 dependent mechanism [146], making it conceivable that tight 
junctions in the gut are similarly effected by bile salts under the control of dopa-
mine. It is well known that bile salts upregulate the orphan X receptors Farnesoid X 
Receptor (FXR), Liver X Receptor (LXR), Retinoid X Receptor (RXR) and PPAR. 
These nuclear receptors regulate the metabolism and homeostasis of glucose and 
lipids in numerous ways, including the transcription of the genes that regulate 
energy metabolism. Beyond the role of lipids in cell membranes and myelin sheaths, 
there is a growing body of literature to support the concept that lipids play a crucial 
signaling and regulatory role in cognition and other CNS events. This would appear 
to be significant as the brain comprised fundamentally of lipid and has the highest 
rate of glucose utilization in the body.
While it is commonly stated that autism occurs more frequently in males, at a 
rate of 4 boys for each girl [147], it is less commonly known that in severe autism 
this ratio increases to 11 to 1 [148]. Numerous sexual dimorphisms in the brain 
have been described (reviewed in [149]), such as brain size, hemispheric com-
munications, differential gene expression, and more. It is worth noting that there 
is a growing body of literature implicating dopamine modulation of behavior as 
part of these sexual dimorphisms. One mechanism which may underlie the sexual 
dimorphism seen in the expression of ASD may relate to SRY, the sex-determining 
region on the Y chromosome, which is responsible for many male traits, including 
the differentiation of bipotential embryonic gonads to become testes. SRY is an 
intronless gene that co-localizes with dopaminergic neurons in the hypothalamus, 
frontal and temporal cortex, striatum, ventral tegmental area (VTA), locus 
coeruleus and substantia nigral. In humans, SRY expression is found in a popula-
tion of TH positive neurons in the VTA, which is the origin of the dopaminergic 
cell bodies of the mesocorticolimbic dopamine system which is widely implicated 
in the drug and natural reward circuitry of the brain. It is important in cogni-
tion, motivation, orgasm, drug addiction, intense emotions relating to love, and 
several psychiatric disorders. SRY has been found to regulate the transcription of 
TH via the AP-1 binding site on the TH promotor. The synthesis of MAO-A, an 
enzyme which inactivates DA, and which has polymorphisms associated with the 
severity of ASD, is also mediated by SRY in a manner that elevates extracellular 
dopamine. Thus, SRY appears to be expressed in regions of the brain, and have 
pharmacologic activity on dopaminergic function, in a manner that is consistent 
with the preponderance of ASD in males that is pathognomic for this syndrome 
(reviewed in [149]).
Consistent with the increased prevalence of ASD in males, work in a mouse 
model has shown that a 16p11.2 gene deletion, which is associated with autism, 
affects the striatal reward system. While both sexes had 50% reductions in mRNA 
associated with ERK1, an important signaling kinase, in males there was an increase 
in ERK1 activation at baseline and in response to sugar in a manner associated with 
reduced striatal plasticity not shown in females. These changes were associated with 
an overexpression of dopamine D2 receptors in the striatum [150].
A mechanism by which sleep disturbances associated with ASD may be medi-
ated involves the striatum, an area known to coordinate reward, learning and 
cognitive behaviors [151, 152] as well as to modulate circadian locomotor and 
retinal responses [153, 154]. This locus has been shown to be responsible for the 
maintenance of normal circadian rhythm functionality, and this system appears to 
be controlled by dopamine. Activation of D2 receptors has been found to regulate 
clock genes in the striatum, controlling circadian events. Hood et al. [155] found 
that depletion of striatal dopamine by various methods, including the use of 
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AMPT, blunts normal circadian functions and that daily dopaminergic activation is 
required to maintain normal circadian rhythmicity.
In the context of a dopamine mediated model of autism, it is interesting to note 
that bile acids under catecholamine control inhibit the GABAA receptor [156, 157] 
in a manner that that diminished GABA related inhibitory post synaptic potentials. 
Inhibition was observed to occur in a stereospecific receptor-ligated, ion channel 
dependent manner, independent of lipophilicity, and consistent with the behavior 
of other known GABA receptor blockers. Interestingly, the inhibitory potencies of 
various bile salts corresponded best with their binding constants with albumin.
Taken together there is evidence for a dopaminergic system which might under-
lay and unite the symptoms of autism which manifest as central nervous system 
changes in mood, attention, cognition, socialization, etc., and those seen in the gut 
as changes in secretory, digestive and excretory functions.
6. The role of energy metabolism
ASD and energy metabolism are associated in several ways beyond the gut 
with glucose and lipid metabolism affected. Key among them is the role of bile 
salts under the control of catecholamines. Bile regulates FXR, LXR, and PPAR 
which are involved in the regulation of glucose metabolism, insulin sensitivity, 
lipid signaling and homeostasis. As a class, these ligand-inducible receptors are 
upregulated in the presence of their ligand, such as bile salts, and after binding 
they migrate to the nucleus where they exert genomic and epigenomic effects upon 
transcription and translation of the genes that mediate glucose and lipid utilization 
(for reviews see: [158–165]).
Diabetes and metabolic syndrome are recognized comorbidities of ASD [154]. 
Catecholamines regulate bile acid release and the FXR upregulates the synthesis and 
secretion of bile salts from the gall bladder by stimulating the bile salt efflux pump 
in order to provide bile to solubilize fat soluble nutrients and vitamins from the gut 
and may have a similarly stimulate FXR in the brain. In mice, FXR deficiency leads 
to insulin resistance and reduced glucose tolerance [163, 166, 167], and the finding 
of FXR in pancreatic islet cells that affects insulin release allows for a regulatory role 
of local bile acid concentrations in insulin release and glucose tolerance [168, 169]. 
In the CNS, it is commonly known that the influence glucose receptors in the hypo-
thalamus, carotid bodies, and other sites summate to mediate the central nervous 
control of glucose metabolism. Eating, satiety and similar energy mediated events in 
the brain are known to be modulated by the sympathetic nervous system, predomi-
nantly by dopaminergic systems [170]. Sympathetic afferents from the hypothalamus 
and other central site, under the control of various agents such as catecholamines 
and leptin are known to regulate glucose synthesis, insulin sensitivity and similar 
events (reviewed in [171–174]). Severing the autonomic projections to the islets of 
Langerhans resulted in a 75–90% impairment in the ability to regulate serum glucose 
in response to insulin induced hypoglycemia [175]. Although the effects of catechol-
amines on lipid homeostasis have been defined in the gut, these mechanism can also 
serve as a model in brain tissue, since this organ contains 25% of the body’s choles-
terol but only 2% of its mass [176], and most of the lipid synthesis and metabolism in 
the brain occurs de novo within the CNS.
There exists a growing body of work that lipid metabolism underlies cognitive 
function. Accumulating evidence supports the idea that HDL and the mechanisms 
that regulate lipid metabolism also influence neurodegenerative diseases includ-
ing autism, amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, 
and others [177]. Just as HDL have a demonstrably cardio-protective role, they 
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also appear to have a neuro-protective role. HDL are made throughout the body 
and serve to remove excess cholesterol from peripheral tissues for excretion in 
the bile and for steroidogenesis. In a study of 139 centenarians it was found that 
plasma HDL correlated with mental acuity in age [178]. This was confirmed in 
another study of 159 centenarians [179], again in a longitudinal population study in 
Amsterdam [180], and supported by the finding that low HDL was associated with 
intellectual impairment in age [181–183]. Effectors like cholesteryl ester transfer 
protein (CETP), which increase HDL are similarly associated with durable cognitive 
function in later age [179, 184, 185].
Bile salts can be released inappropriately via a “leaky gut” syndrome that ASD 
or they can be made locally in the brain under the control of catecholamines. Their 
synthesis and biologic functions have been described in a variety of non-gastric 
tissues, including the brain. As reviewed by Quinn and DE Marrow [186], bile acids 
and their salts are now viewed as steroid hormones, and not merely as detergents 
that solubilize lipids. Consistent with their role as the predominant brain steroid 
[145], in the rat that the primary bile acid chenoxydecholic acid composed 95% of 
brains bile acid. Further, the most abundant oxysterols found in the CNS are the C22 
and C26 intermediates of bile acid synthesis.
One of the agents that regulates HDL homeostasis is the LXR, which is upregu-
lated in the presence of the bile salts that solubilize and accompany plasma and 
tissue lipids. LXR is a cholesterol sensing and regulating molecule and cholesterol 
functionality is necessary for heathy cell membrane function, which is crucial to 
synaptic function. LXR has been demonstrated to improve cognitive performance 
in animal models of Alzheimer’s disease presumably via the induction of HDL 
[cited: [177]].
Once believed to be the master regulator of glucose and lipid metabolism, 
PPAR-γ is associated with the maturation and development of adipocytes, the 
deposition of lipids, glucose metabolism, insulin sensitivity and other related 
events [187]. PPAR-γ has been shown to be mediated by bile salts and dopamine 
via phospholipase C in a calcium dependent manner, with elevations in dopamine 
resulting in increased PPAR-γ in cardiac myocytes [188]. PPAR-α is abundantly 
expressed in skeletal muscle, liver and brain [189, 190], and is associated with 
dyslipidemia, a condition often seen in autistic patients [190–193]. PPAR-α has 
been associated in the literature with central dopaminergic function as it appears to 
influence the activity of antipsychotic agents known to interact with dopaminergic 
neurologic systems [194, 195]. It has also been implicated in reduced GABAergic 
interneuron firing in pyramidal neurons resulting in cortical excitation [196–199]. 
D’Agastino et al. [200] have shown that central nervous system reduction in this 
“Master Regulator of Lipid Homeostasis” is associated with autistic like behaviors 
that include; repetitive and perseverative behaviors, loss of cognitive flexibility and 
reduced spatial information processing. They documented PPAR-α deprivation 
resulted in resistance to central glutamate stimulation via NMDA receptors, reduced 
GABAergic interneurons in the frontal cortex and hippocampus with dystrophic 
neurons in these structures, and increased gamma waves with decreased theta wave 
frequency.
Historically, there is a well-defined relationship between stress, catecholamines, 
and plasma lipids (reviewed in [25]). Stress, which is characterized by elevated 
levels of circulating catecholamines, is associated with increased plasma lipids, 
reduced glycemic control, diminished insulin secretion and insulin insensitivity, 
all of which can be associated with ASD. This is consistent with the aggressive 
fighting responses associated with catecholamines significantly elevating NGF in 
sympathetic ganglia and in the absence of ACTH or corticoids [201]. Various central 
mechanisms have been implicated in these events, including, the ventromedial 
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nucleus of the hypothalamus and hippocampal efferents to the hypothalamus. 
These central nervous system events can be translated into hyperlipidemia in three 
ways: via adrenal epinephrine release, via elevated pancreatic glucagon secretion, 
and via the regulation of hepatic glycolysis and gluconeogenesis. All three of these 
pathways are regulated by the sympathetic nervous system.
These findings fit with an emerging metabolic model of autism in which CNS 
control of energy metabolism and the autonomic nervous system as an integrating 
modality that senses and regulates those changes in the periphery and modifies 
these effects centrally. Integration of reward, satiety, insulin release and sensitivity, 
related endocrine events, as well as circadian clock mechanisms and similar systems 
which are impaired in autism appear to be mediated largely in the hypothalamus 
and brain stem via various nutrient sensing mechanisms which reticulate through-
out the CNS to the cortex, basal ganglia, pyramids and so forth. (for a review see 
[202]). Cholesterol, LXR, PPARs and other agents which are known to regulate 
energy metabolism in the periphery appear to do so in the CNS as well and these 
mechanisms map well to the deficiencies seen in autism. It is particularly note-
worthy that many of the events mediated by the nuclear receptors LXR and PPAR 
are cell and ligand specific, and that changes in cholesterol metabolism can have 
profound changes on membranes and their functions. That these changes can vary 
as a function of cell type provides a mechanism by which metabolic impairments in 
discrete brain regions may occur in ways that compromise specific nuclei and tracts.
Taken together, there appears to be linkage between catecholamine metabolism 
both centrally and peripherally, the regulation of energy homeostasis, and central 
nervous system function in a variety of pathologic states. There is a growing body of 
evidence to indicate a relationship between central and peripheral nervous system 
regulation of glucose and energy homeostasis, and abnormal cognitive function, as 
exemplified in autism.
7. Nerve growth factors
Nerve growth factor (NGF) in the brain is stimulated by catecholamine synthe-
sis [203] and regulates the morphology of the catecholamine synapse. Neurotropic 
NGF is required for catecholaminergic neuron survival and differentiation. It 
is released into the synapse with catecholamines and it determines the synaptic 
architecture with elevated levels of NGF resulting in elevated levels of TH, cate-
cholamine synthesis and synaptic neurotransmission [204–206] since NGF con-
centrations have a direct effect on the budding and arborization of catecholamine 
dendrites [207, 208] as well as the density of target tissue innervation [209, 210] 
Similarly, elevated catecholaminergic transmission is associated in a dose dependent 
manner with brain derived nerve growth factor (BDNF) in a pre-synaptic manner 
[211]. This is consistent with the finding that the loss of a Brain Derived Nerve 
Growth Factor (BDNF) allele in a mouse knockout model.prevented the loss of 
sympathetic islet innervation in an immune based diabetic model [212].
NGF has a hyperplastic, hypertrophic effect on catecholaminergic neurons 
characterized by elevated TH [213–215] that results from binding to its tyrosine 
kinase receptor TrkA expressed on the axons of catecholaminergic neurons [216]. 
In this way pre-synaptic release of neurotransmitters exerts a differentiating effect 
post-synaptically to mediate catecholamine synaptic architecture, the number of 
neurons, and innervation density [207, 217].
NGF is known to increase with increased catecholaminergic nerve traffic and 
with stress [218], and results in the sprouting of new nerve fibers in the stellate 
ganglion and elsewhere in the sympathetic nervous system [219, 220]. NGF and 
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BDNF are important mediators of neurologic function in the brain with the abil-
ity to mediate short and long term neurologic function in areas associated with 
ASD like the cortex and hippocampus [221, 222]. NGF has been shown to promote 
sympathetic neural growth, differentiation and to enhance target innervation 
[205, 208–210, 223, 224] and NGF is known to be elevated in PTSD [225–227], 
a disease with a similar constellation of symptoms to autism. NGF leads to 
sympathetic sprouting and supports dendritic geometry of the newly sprouted 
nerve terminals for the life of the sympathetic neural substrate [228, 229]. NGF 
is known to effect memory directly [230], indirectly [220, 231, 232], and through 
its actions on NE, as well as indirectly via hypothalamically mediated release of 
cortisol [233].
8. L1-79
LI:79 is D,L α-methyl-para-tyrosine, abbreviated AMPT. It inhibits the activity 
of TH, which catalyzes the first transformation in catecholamine biosynthesis, i.e., 
the conversion of tyrosine to dihydroxyphenylalanine (DOPA) which is the rate 
limiting step in catecholamine synthesis. L α-methyl-para-tyrosine was approved 
by the FDA in 1979, is marketed under the name Demser®, and is typically called 
metyrosine and abbreviated AMT.
α-methyl-para-tyrosine is a tyrosine analog that competes competitively for TH 
and is excreted mostly unchanged in the urine. Demser was approved for presurgi-
cal use in the treatment of pheochromocytoma, a catecholamine producing tumor 
which when manipulated surgically releases pathologic levels of catecholamines 
into the circulation that can result in serious AE. Demser minimizes this potentially 
serious complication and can treat pheochromocytoma patients who were not quali-
fied for surgery. It is approved for use in doses between 1 and 4 g/day in divided 
doses. The doses of L1-79 used in autism clinical trials was 90 mg tid to 400 mg tid 
of which only 50% is the L-isomer.
While Demser is intended to deplete adrenal medullary catecholamines as fully 
as possible L1-79 is intended to reduce catecholaminergic tone slightly, a use for 
which Demser is inappropriate. The published half-life for Demser is 3.53 hours 
[234], whereas the half-life for L1-79 has been found to be between 10.3–14.3 hours 
[235]. This is presumed to result from a competitive inhibition between the dextro 
and levo forms of the molecule for the L-amino acid transport mechanisms in the 
body resulting in more time on target for the racemate. Since only 50% of L1-79 is 
the active L-isomer, and as it persists at the receptor for a longer duration, L1-79 is 
suitable for bid dosing and is much better tolerated at the lower doses used to get a 
therapeutic effect in ASD.
Adverse events associated with Demser include sedation that typically habitu-
ates but might persist at doses >2 g/d, temporary changes in sleep, extrapyramidal 
signs including tremor at high doses, trismus and parkinsonism at high doses, dose 
dependent confusion that resolves with dose reduction, dose related diarrhea, and 
infrequent AE that include crystalluria, nausea and vomiting, and impotence. None 
of these have been observed in autism except for 2 patients who manifest crystal-
luria without clinical consequence at the 200 mg tid dose.
It should be noted that D,L α-methyl-para-tyrosine as described herein for the 
treatment of autism is also used in a polytherapeutic regimen for the treatment 
of patients with late stage cancer (SM-88) under the Tyme Technologies Inc. at 
doses that are a fraction of the lowest approved dose for Demser, and has been well 
tolerated.
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9. Preliminary clinical observations
In a proof of concept trial in 8 patients of both sexes between the ages of 2.75 
to 24 years of age and without Rett or Fragile X syndrome. Doses began at doses 
of 90 mg tid and were escalated to 200 mg tid for most patients with two patients 
receiving a brief course at 400 mg tid, which was not found to increase efficacy. 
All doses were well tolerated. Patients were washed out of their legacy medications 
and 6 patients were maintained on L1-79 alone. Two patients were restarted on one 
of their legacy medications at lower than their pre-study dose. L1-79 in this study 
had a therapeutic effect on the core symptoms of autism as defined by the ABC-C 
(Figure 1), the CPRS (Figure 2), ADOS (Figure 3), and the CGI (Figure 4). This 
includes improvements in socialization, communication, repetitive movements, 
sleep disturbances, and other symptoms of ASD. Interestingly, the Autism Diagnostic 
Observation Schedule 2 (ADOS), which is the “gold standard” for quantifying the 
lifetime severity of ASD was profoundly influenced by L1-79 treatment. In the 6 
patients in whom the ADOS was measured a mean decrease of 30% was observed 
with one patient experiencing a reduction of 47% (Figure 3) which took him below 
the threshold for a diagnosis of autism following 10 weeks of treatment, although 
Figure 1. 
Proof of concept study: Aberrant behavior checklist-community (ABC-C) scores. Domain scores for each 
participant during weeks 1 to 8. Because of participant-specific factors, ABC-C scores were not recorded at all 
visits for all participants.
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Figure 3. 
Proof of concept study: Autism diagnostic observation schedule (ADOS) scores for the 6 participants tested at 
baseline and week 10.
Figure 2. 
Proof of concept study: Connor parent rating scale (CPRS) at 4-week intervals for 8 participants. Some 
participants did not have all assessments.
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he was still on the spectrum [236]. As can be seen in the ABC-C scores, these effects 
were observed rapidly.
A follow-up randomized, double blind, placebo-controlled 28-day study of 
39 patients has been completed and the results are currently in preparation for 
publication [237]. While 28 days was too short to demonstrate much of an effect, 
per the FDA the existing toxicology did not permit a longer treatment duration at 
that time. Participants were male patients between the ages of 13 and 21 years of 
age with a diagnosis of ASD based on DSM-5 criteria and confirmed by Autistic 
Diagnosis Interview-Revised (ADI-R), ADOS and expert clinical opinion, stable 
on no more than one concomitant medication with no planned changes in psy-
chosocial interventions during the study and sufficiently tolerant and capable 
of complying with the requirements for this study. Results from this brief study 
can be seen for the CGI (Figure 5), Social Response Scale-2 (SRS) social motiva-
tion T scores (Figure 6), ADOS (Figure 7), Vinland Adaptive Behavior Scale-II 
(VABS) socialization standard score (Figure 8), and the SRS DSM-SCI T scores 
(Figure 9).
Anecdotally, numerous salutary behaviors were observed in these studies. Two 
teenage boys hugged and kissed their parents for the first time. One teenager with 
a history of self mutilating behavior stopped hurting himself. Subjective aspects 
of socialization such as empathy, effective communication, emotional expression, 
better sleep patterns, and engagement with peers were reported by parents and 
teachers and a school bus driver who were unaware of the trials.
The proof of concept study was conducted under the assumption that, per 
the 505(b)(2) guidelines, any stereoisomer of a drug is considered to be the same 
drug, and therefore the use of L1-79 was an unapproved use of an approved agent 
(Demser). In subsequent discussions with the FDA this was disallowed. The FDA 
required that the proof of concept study be discontinued and approved a follow-on 
pilot study that was limited to 28 days based upon the toxicology then in existence. 
It is noteworthy that when study drug was discontinued after the 28-day pilot 
study patients regressed to baseline within one week whereas the proof of concept 
patients who had been on study drug for as long as 6 months maintained some 
residual benefit following the discontinuation of medication.
Figure 4. 
Proof of concept study: Clinical global impressions (CGI) scores for 8 participants. Top panel shows 
absolute scores at week 1 and week 8. Bottom panel shows the change from week 1 to week 8. The qualitative 
interpretation at week 1 appears above each participant change in score, and the interpretation at week 8 is 
shown below each bar. Each participants efficacy index at week at appears at the bottom.
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Figure 6. 
Change from baseline over time and individual patient responses in the social responsiveness Scale-2 (SRS-2) 
social motivation T-score at week 4. Upper panel is change from baseline over time for L1-79 200 mg and 
placebo. Lower panel is individual changes for L1-79 200 mg and placebo.
Figure 5. 
Pilot study: Change in clinical global impression-severity (CGI-S) over time and individual patient responses 
from baseline to week 4. Upper panel is the change over time by study week for L1-79 200 mg and placebo. The 
lower panel is individual patient responses for L1-79 200 mg and placebo.
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Figure 7. 
Pilot study: ADOS score changes for 200 mg dose and placebo after 28 days of treatment. Negative scores 
represent improvement.
Figure 8. 
Upper panel: Change from baseline over time and individual patient responses Vineland adaptive behavior-II 
(VABS) socialization standard score at week 4 for L1-79 200 mg and placebo. Lower panel individual changes 
for L1-79 200 mg and placebo.
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10. Mechanism of action
We hypothesize that the mechanism begins with some process that stimulates 
massive levels of sympathetic neural traffic that gives rise to high levels of catechol-
amine synthesis and release which is associated with high levels of both BDNF and 
NGF [238]. NGF receptors are found on sympathetic nerves [239] and are respon-
sible for maintaining catecholaminergic synaptic architecture due to their control 
on the budding and arborization of catecholamine dendrites [207, 208] and density 
of innervation [209, 210].
Elevated levels of synaptic nerve growth factors associated with catecholamine 
release may result from a variety of factors including genetics, cognitive or biologi-
cal stress such as exposure to pesticides, fever in utero, complications of pregnancy, 
or other causes. This catecholamine elevation results in elevated levels of nerve 
traffic due to growth factor induced budding and arborization of catecholamine 
Figure 9. 
Pilot study: Upper panel is the change from baseline over time in the social responses scale – 2 DSM-SCI for 
week 4 L1-79 200 mg and placebo. Lower panel individual changes for L1-79 200 mg and placebo.
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nerve terminals and collaterals. As these growth factors are required to support 
the dendritic architecture of the neurons over their life, this elevated level of NGF 
& BDNF become chronic, resulting in an enhanced level of synaptic morphology 
and a consequent elevation of catecholamine release from these new hypertrophic 
synapses. This change in the level of catecholaminergic tone and the elevated 
release of catecholamines creates a persistent imbalance in the CNS and between 
the sympathetic and parasympathetic arms of the autonomic nervous system result-
ing in an overstimulation of some tracts and depletion in others. This imbalance 
caused by the growth factors centrally and peripherally results in both neurologic 
and metabolic pathology.
Because this involves catecholaminergic mechanisms in the brain, gut, mes-
entery, and elsewhere in the body, changes in emotional expression, speech, 
cognition, memory, circadian rhythms, gut function, energy metabolism, and the 
entire panoply of autism related symptoms can potentially be ascribed to aberrant 
catecholaminergic function. It is worth noting that NGF exerts presynaptic func-
tionality with both pre- and post-synaptic effects with both short- and long-term 
effects on catecholaminergic neurotransmission [216]. Thus, the effects of L1-79 
are not mimicked by receptor blocking agents which only reduce post-synaptic 
depolarization but do nothing to address the underlying abnormality of excessive 
catecholaminergic collaterals and a hypertrophic dendritic architecture induced and 
maintained by growth factors.
Since NGF is known to stimulate TH [215, 240–242] and L1-79 inhibits TH, 
and given both the short and long term effects of NGF exposure on sympathetic 
substrates, L1-79 is likely to have a therapeutic effect in the short and intermediate 
term of treatment of autism and may even have a disease modifying effect in the 
long run if the hypertrophic synaptic architecture regresses to a more homeostatic 
morphology. That is, if the underlying pathology of ASD is due in whole or part due 
to elevated catecholaminergic tone due to the release of growth factors associated 
with catecholamine release, then by reducing catecholamine synthesis, storage and 
release along with the associated release of NGF and BDNF a reduction of symp-
toms is likely to result. If, over a longer period, the reduction of NGF and BDNF 
enables a restoration of normal synaptic morphology then a persistent reduction of 
ASD symptoms may be possible, even in the absence of treatment.
11. Conclusions
L1-79 inhibits the rate limiting step in the synthesis of catecholamine, including 
dopamine and norepinephrine. Unlike the L-isomer of AMPT (Demser), L1-79 has 
a better kinetic profile for the use of L1-79 as a treatment for ASD. It’s presynaptic 
mechanism of action likely results in a diminution of both catecholamines and related 
growth factors which we hypothesize will reduce symptoms of ASD in a manner 
not possible with receptor blockers, and which with long term use may reduce the 
hypertrophic architecture of catecholamine synapses in ASD back to a homeostatic 
morphology. An exaggerated catecholaminergic mechanism underlying ASD and its 
associated comorbidities can explain a variety of potential influences on the disease 
including the effects of bile, orphan receptors, lipids, glucose and other factors.
Preliminary results observed following the administration of L1-79 to autistic 
juveniles and adolescents has resulted in consistent improvement in the core symp-
toms of in two early studies [214, 215] not seen with previous agents.
L1-79 appears to be an effective therapy for the treatment of autism in children 
empirically with a novel mechanism of action that is supported by the scientific 
literature.
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